QNP: Gastrointesinal Lesion Software Detection System

Product code QNP, “Gastrointesinal Lesion Software Detection System” in FDA's classification database, is a Class II device type under 21 CFR 876.1520 (gastrointestinal lesion software detection system), reviewed by FDA's Gastroenterology, Urology panel. FDA's 510(k) database lists 23 clearances under QNP, 23 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
QNP
Regulation
21 CFR 876.1520
Class
II
Panel
Gastroenterology, Urology
Clearances
23
Most recent
Sep 12, 2026
Median review, last 2 years
32 days
Third-party review
Not eligible
Implant
No

What it covers

A gastrointestinal lesion software detection system is a computer-assisted detection device used in conjunction with endoscopy for the detection of abnormal lesions in the gastrointestinal tract. This device with advanced software algorithms brings attention to images to aid in the detection of lesions. The device may contain hardware to support interfacing with an endoscope.

FDA’s definition of product code QNP, from the Product Classification database.

Recent clearances

510(k)DeviceApplicantDecisionType
K260133CADDIEOdin Medical LimitedSep 12, 2026Special
K260567EW10-EC02 Endoscopy Support ProgramFujifilm CorporationAug 7, 2026Special
K252853CAD - Lower GI (EC07-01)Xiamen Inno Medical Technology Co., Ltd.Aug 5, 2026Traditional
K261369GI Genius™ Module 300 (GGM300-US);ColonPRO™ US (CPRO403S-US)Cosmo Artificial Intelligence - Ai, Ltd.May 29, 2026Special
K260724MAGENTIQ-COLO (ME-APDS)Magentiq Eye, Ltd.Apr 3, 2026Special
K253664SKOUT systemIterative HealthDec 22, 2025Special
K252178MAGENTIQ-COLO (ME-APDS)Magentiq Eye, Ltd.Oct 3, 2025Special
K252586CADDIEOdin Medical LimitedSep 12, 2025Special
K251126SKOUT systemIterative HealthMay 9, 2025Special
K244023MAGENTIQ-COLO (ME-APDS)Magentiq Eye, Ltd.Jan 24, 2025Special
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 23 with a free account)

Clearances by year

23 QNP 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)5169
2025528
2024529
20234140
20221263
20213203

Who submits

8 applicants cleared a QNP device since 2011. 26% of the clearances went to applicants in Ireland, then United States (26%), Israel (17%) and United Kingdom (13%). By type: Special 70%, Traditional 26% and Direct 4%.

ApplicantClearances since 2011
Cosmo Artificial Intelligence - Ai, Ltd.6
Iterative Scopes, Inc.4
Magentiq Eye, Ltd.4
Odin Medical Limited3
Fujifilm Corporation2
Iterative Health2
Chengdu Wision Medical Device Co., Ltd.1
Xiamen Inno Medical Technology Co., Ltd.1

How FDA classifies it

Class II (special controls). The special controls for this device are:

(1) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including detection of gastrointestinal lesions and evaluation of all adverse events.

(2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Testing must include:

(i) Standalone algorithm performance testing;

(ii) Pixel-level comparison of degradation of image quality due to the device;

(iii) Assessment of video delay due to marker annotation; and

(iv) Assessment of real-time endoscopic video delay due to the device.

(3) Usability assessment must demonstrate that the intended user(s) can safely and correctly use the device.

(4) Performance data must demonstrate electromagnetic compatibility and electrical safety, mechanical safety, and thermal safety testing for any hardware components of the device.

(5) Software verification, validation, and hazard analysis must be provided. Software description must include a detailed, technical description including the impact of any software and hardware on the device's functions, the associated capabilities and limitations of each part, the associated inputs and outputs, mapping of the software architecture, and a description of the video signal pipeline.

(6) Labeling must include:

(i) Instructions for use, including a detailed description of the device and compatibility information;

(ii) Warnings to avoid overreliance on the device, that the device is not intended to be used for diagnosis or characterization of lesions, and that the device does not replace clinical decision making;

(iii) A summary of the clinical performance testing conducted with the device, including detailed definitions of the study endpoints and statistical confidence intervals; and

(iv) A summary of the standalone performance testing and associated statistical analysis.

From 21 CFR 876.1520. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 876.1520 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent QNP clearances declared.

Ask about QNP

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about QNP

What is FDA product code QNP?

Product code QNP, “Gastrointesinal Lesion Software Detection System” in FDA's classification database, is a Class II device type under 21 CFR 876.1520 (gastrointestinal lesion software detection system), reviewed by FDA's Gastroenterology, Urology panel. FDA's 510(k) database lists 23 clearances under QNP, 23 of them since 2011.

How many 510(k) clearances are there under QNP?

FDA’s 510(k) database listed 23 clearances under QNP as of Oct 29, 2026, 23 of them decided since 2011; the most recent decision was Sep 12, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a QNP 510(k)?

For the 10 QNP clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 32 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most QNP clearances?

Since 2011: Cosmo Artificial Intelligence - Ai, Ltd. (6), Iterative Scopes, Inc. (4), Magentiq Eye, Ltd. (4), Odin Medical Limited (3) and Fujifilm Corporation (2). 8 applicants have cleared a QNP device in that time.

Sources

  1. FDA product classification: QNP · Product Classification database
  2. 21 CFR 876.1520: Gastrointestinal lesion software detection system · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for QNP · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow QNPGet an email when FDA clears, recalls or publishes guidance for QNP devices.

Know what FDA already cleared.